DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 7,201.920 B2 Kumar Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 7,201.920 B2 Kumar Et Al US007201920B2 (12) United States Patent (10) Patent No.: US 7,201.920 B2 Kumar et al. (45) Date of Patent: Apr. 10, 2007 (54) METHODS AND COMPOSITIONS FOR 6,153,621 A 11/2000 Hamann DETERRING ABUSE OF OPOD 6,228,863 B1 5, 2001 Palermo et al. CONTAINING DOSAGE FORMS 6,309.668 B1 10/2001 Bastin et al. 6,352,721 B1 3/2002 Faour (75) Inventors: Vijai Kumar, Morris Plains, NJ (US); 6,375,957 B1 4/2002 Kaiko et al. David Dixon, Woodside, NY (US); 6,491,949 B2 12/2002 Faour et al. s ina: 6,559,159 B2 5/2003 Carroll et al. Divya Tewari, Suffern, NY (US); Dilip 6,572,885 B2 6/2003 Oshlack et al. B. Wadgaonkar, Suffern, NY (US) 6.593,367 B1 7/2003 Dewey et al. 2003/OOO4177 A1 1/2003 Kao et al. (73) Assignee: Acura Pharmaceuticals, Inc., Palatine, 2003, OO64099 A1 4/2003 Oshlack et al. IL (US) 2003, OO64122 A1 4/2003 Goldberg et al. 2003, OO68276 A1 4/2003 Hughes et al. (*) Notice: Subject to any disclaimer, the term of this 2003-0068370 A 42003 Sackler patent is extended or adjusted under 35 2003/0068375 A1 4/2003 Wright et al. U.S.C. 154(b) by 476 days. 2003.0068392 A1 4/2003 Sackler et al. 2003/O124061 A1 7/2003 Roberts 2003/O1241.85 A1 7/2003 Oshlack et al. (21) Appl. No.: 10/723,654 2003/O125347 A1 7/2003 Anderson et al. 1-1. 2003/0170181 A1 9, 2003 Midha (22) Filed: Nov. 26, 2003 2003/0232081 A1 12/2003 Doshi et al. O O 2004/O131552 A1 7/2004 Boehm (65) Prior Publication Data 2004/0151791 A1 8/2004 Mayo-Alvarez US 2005/O112O67 A1 May 26, 2005 2004/0228802 Al 11/2004 Chang et al. s 2005.0020613 A1 1/2005 Boehm et al. 2005, OO63909 A1 3/2005 Wright et al. (51) Int. Cl. 2005/0106249 A1 5/2005 Hwang9. et al. 3. 32. 3.08: 2006, OO18837 A1 1/2006 Preston et al. A6 IK3I/35 (2006.01) FOREIGN PATENT DOCUMENTS A6 IK 3/485 (2006.01) WO WO 2003 O26743 A2 4, 2003 A6 IK 3/4468 (2006.01) WO WO 2004/O26256 A2 1/2004 AOIN 43/647 (2006.01) WO WO 2004/O26283 4/2004 AOIN 43/40 (2006.01) WO WO 2004/037259 A1 5, 2004 AOIN 43/46 (2006.01) OTHER PUBLICATIONS (52) U.S. Cl. ...................... 424/454: 514/282: 514/242: 514/333; 514/277: 514/766: 514/214.03; Wells, Mickey L. and, Eugene L. Parrott. “Effect of Anionic 514/740, 514/747: 514/764 Surfactants on the Release of Chlorpheniramine Maleate From an (58) Field of Classification Search ................ 424/451. Inert, Heterogeneous Matrix.” Drug Development and Industrial s Pharmacy 18(2) (1992): 175-186. 424/408, 454; $14,282 .....' Rao, B. Sreenivasa and K.V. Ramana Murthy. “Effect of Sodium lication file f 1 h hi s Lauryl Sulfate on the Release of Rifampicin from Guar Gum See application file for complete search history. Matrix.” Indian Journal of Pharmaceutical Science (2000): 404 (56) References Cited 406. Matschiner et al., “Characterization of Ion Pair Formation Between U.S. PATENT DOCUMENTS Erythromycin and Lipophilic Counter Ions.” Pharmazie 50 (1995): 462-464. 3,065,143 A 11, 1962 Christenson et al. 3.260,646 A 7, 1966 Paulsen et al. Primary Examiner Johann R. Richter 4,070,494 A 1/1978 Hoffmeister et al. Assistant Examiner James H. Alstrum-Acevedo 4,175,119 A 11, 1979 Porter (74) Attorney, Agent, or Firm Morgan Lewis & Bockius 4.389,393 A 6, 1983 Schor et al. LLP 4,457.933 A 7, 1984 Gordon et al. 4.459.278 A 7, 1984 Porter (57) ABSTRACT 4,599,342 A 7, 1986 LaHann 4,610,870 A 9, 1986 Jain et al. This invention relates to an abuse deterrent dosage form of 4,666,705 A 5, 1987 DeCrosta et al. opioid analgesics, wherein an analgesically effective amount 5,059,600 A 10, 1991 Gawin et al. 5,114,942 A 5, 1992 Gawin et al. of opioid analgesic is combined with a polymer to form a 5.330,766 A 7, 1994 Morella et al. matrix. 5,741,524 A 4, 1998 Staniforth et al. 5,968,551 A 10, 1999 Oshlack et al. 54 Claims, 9 Drawing Sheets U.S. Patent Apr. 10, 2007 Sheet 1 of 9 US 7,201.920 B2 Extractin f Opioids from immediatel controlled release formulations t O O w E wd Od O O s U d x c C u O SS Oxycodone Hydrocodone Oxycontins" Hydrochloride Bitaritrate (Controlled release) (lmmediate release) (immediate release) Fig. 1 U.S. Patent Apr. 10, 2007 Sheet 2 of 9 US 7,201.920 B2 Extraction f Opioids from anti-abuse formulation 100 80 60 40 20 O Oxycodone Hydrocodone Morphine Hydrochloride Bitatrate Sulfate (Immediate release) (Immediate release) (Immediate release) Fig. 2 * Extraction process of opioids for anti-abuse properties is the same for figure 1 and figure 2. ** Marketed Oxycodone formulation from Purdue Pharma. U.S. Patent Apr. 10, 2007 Sheet 3 of 9 US 7.201.920 B2 ºu?sºI,9SnqVJOS?InsòYI suopelnuuJOJI3?IS9u0p000.IpÁH peoeux find 9/ U.S. Patent Apr. 10, 2007 Sheet 4 of 9 US 7,201.920 B2 SnO?IBAJOSÐI?OJAUIO!]n[OSSICI s????pmorsmopošo oQ!06080/09090,708OZ01 (sº)nu?uu)au?L 00! pe NIOSSIO find % U.S. Patent Apr. 10, 2007 Sheet 5 Of 9 US 7,201.920 B2 Figure 5a U.S. Patent Apr. 10, 2007 Sheet 6 of 9 US 7,201.920 B2 Figure 5b U.S. Patent Apr. 10, 2007 Sheet 7 Of 9 US 7,201.920 B2 Figure 5c U.S. Patent Apr. 10, 2007 Sheet 8 of 9 US 7,201.920 B2 Step 3 Figure 6: Process Flow Chart U.S. Patent Apr. 10, 2007 Sheet 9 of 9 US 7.201.920 B2 18OH‘H siº?quimisiohjoisenyo,nonnossia p0AOSSC 24, US 7,201.920 B2 1. 2 METHODS AND COMPOSITIONS FOR dosage form with a Suitable solvent (e.g., water), and then DETERRING ABUSE OF OPOD Subsequently extracting the opioid component from the CONTAINING DOSAGE FORMS mixture for use in a solution Suitable for intravenous injec tion of the opioid to achieve a “high.” FIELD OF INVENTION 5 Attempts have been made to diminish abuse of orally This invention pertains to abuse deterrent compositions administered opioid drugs. These attempts generally cen containing a drug (e.g., an analgesic opioid). Additionally, tered on the inclusion in the oral dosage form of an opioid antagonist which is not orally active but which will sub the invention relates to a method of administering a dose of stantially block the analgesic effects of the opioid if one an analgesic from a dosage form, which is abuse deterrent. 10 attempts to dissolve the opioid and administer it parenterally. BACKGROUND OF THE INVENTION For example, commercially available Talwin RNX tablets from Sanofi-Winthrop contain a combination of pentazocine The class of drugs exhibiting opium or morphine-like and naloxone. Pentazocine is a partial agonist of LL receptors properties are referred to as opioids, or opioid agonists. 15 and also has affinity for K receptors, whereas, naloxone is an Certain opioids act as agonists, interacting with stereo antagonist of LL receptors. Talwin RNX contains pentazocine specific and Saturable binding sites in the brain and other hydrochloride equivalent to 50 mg base and naloxone hydro tissues. Endogenous opioid-like peptides are present in areas chloride equivalent to 0.5 mg base. Talwin RNx is indicated of the central nervous system that are presumed to be related for the relief of moderate to severe pain. The amount of to the perception of pain; to movement, mood and behavior, 20 naloxone present in this combination has no action when and to the regulation of neuroendocrinological functions. taken orally, and will not interfere with the pharmacologic Three classical opioid receptor types, mu (LL), delta (Ö), and action of pentazocine. However, this amount of naloxone kappa (K), have been studied extensively. Each of these given by injection has profoundantagonistic action to opioid receptors has a unique anatomical distribution in the brain, analgesics. Thus, the inclusion of naloxone is intended to spinal cord, and the periphery. Most of the clinically used 25 curb a form of misuse of oral pentazocine, which occurs opioids are relatively selective for u receptors, reflecting when the dosage form is solubilized and injected. Therefore, their similarity to morphine. However, it is important to note this dosage has lower potential for parenteral misuse than that opioid containing drugs that are relatively selective at previous oral pentazocine formulations. standard doses will often interact with additional receptor U.S. Pat. No. 6,559,159 (Carroll et al.) describes the use Subtypes when given at Sufficiently high doses, leading to 30 of kappa receptors antagonist for the treatment of opioid possible changes in their pharmacological effect. This is related addictions. One Such compound is naltrexone, which especially true as opioid doses are escalated to overcome is commercially available in the tablet form Revia(R) for the tolerance. treatment of alcohol dependence and for the blockade of The potential for the development of tolerance, physical exogenously administered opioids. (Physicians Desk Refer and/or psychological, dependence (i.e., addiction) with 35 ence 57" ed., Montvale, N.J.) repeated opioid use is a characteristic feature of most opioid U.S. Pat. No. 6,375,957 (Kaiko et al.) describes in detail containing drugs. The possibility of developing addiction is the combination of opioid agonist, NSAID, and an orally one of the major concerns in the use of opioids for the active opioid antagonist.
Load more

Recommended publications
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Opioid Receptorsreceptors
    OPIOIDOPIOID RECEPTORSRECEPTORS defined or “classical” types of opioid receptor µ,dk and . Alistair Corbett, Sandy McKnight and Graeme Genes encoding for these receptors have been cloned.5, Henderson 6,7,8 More recently, cDNA encoding an “orphan” receptor Dr Alistair Corbett is Lecturer in the School of was identified which has a high degree of homology to Biological and Biomedical Sciences, Glasgow the “classical” opioid receptors; on structural grounds Caledonian University, Cowcaddens Road, this receptor is an opioid receptor and has been named Glasgow G4 0BA, UK. ORL (opioid receptor-like).9 As would be predicted from 1 Dr Sandy McKnight is Associate Director, Parke- their known abilities to couple through pertussis toxin- Davis Neuroscience Research Centre, sensitive G-proteins, all of the cloned opioid receptors Cambridge University Forvie Site, Robinson possess the same general structure of an extracellular Way, Cambridge CB2 2QB, UK. N-terminal region, seven transmembrane domains and Professor Graeme Henderson is Professor of intracellular C-terminal tail structure. There is Pharmacology and Head of Department, pharmacological evidence for subtypes of each Department of Pharmacology, School of Medical receptor and other types of novel, less well- Sciences, University of Bristol, University Walk, characterised opioid receptors,eliz , , , , have also been Bristol BS8 1TD, UK. postulated. Thes -receptor, however, is no longer regarded as an opioid receptor. Introduction Receptor Subtypes Preparations of the opium poppy papaver somniferum m-Receptor subtypes have been used for many hundreds of years to relieve The MOR-1 gene, encoding for one form of them - pain. In 1803, Sertürner isolated a crystalline sample of receptor, shows approximately 50-70% homology to the main constituent alkaloid, morphine, which was later shown to be almost entirely responsible for the the genes encoding for thedk -(DOR-1), -(KOR-1) and orphan (ORL ) receptors.
    [Show full text]
  • Opioid Imaging
    529 NEUROIMAGING CLINICS OF NORTH AMERICA Neuroimag Clin N Am 16 (2006) 529–552 Opioid Imaging Alexander Hammers, PhDa,b,c,*, Anne Lingford-Hughes, PhDd,e - Derivation, release, peptide action, Changes in receptor availability in pain and metabolism and discomfort: between-group - Receptors and ligands comparisons Receptors Direct intrasubject comparisons of periods Species differences with pain and pain-free states Regional and layer-specific subtype - Opioid imaging in epilepsy distributions Focal epilepsies Ligands Idiopathic generalized epilepsy - Positron emission tomography imaging Summary of opioid receptors - Opioid imaging in other specialties Introduction PET imaging Movement disorders Quantification of images Dementia Available ligands and their quantification Cardiology - Opioid receptor imaging in healthy - Opioid imaging in psychiatry: addiction volunteers - Summary - Opioid imaging in pain-related studies - Acknowledgments - References Opioids derive their name from the Greek o´pioy agonists provided evidence for the existence of mul- for poppy sap. Various preparations of the opium tiple receptors [4]. In the early 1980s, there was ev- poppy Papaver somniferum have been used for pain idence for the existence of at least three types of relief for centuries. Structure and stereochemistry opiate receptors: m, k, and d [5,6]. A fourth ‘‘orphan’’ are essential for the analgesic actions of morphine receptor (ORL1 or NOP1) displays a high degree and other opiates, leading to the hypothesis of the of structural homology with conventional opioid existence of specific receptors. Receptors were iden- receptors and was identified through homology tified simultaneously by three laboratories in 1973 with the d receptor [7], but the endogenous ligand, [1–3]. The different pharmacologic activity of orphanin FQ/nociceptin, does not interact directly Dr.
    [Show full text]
  • Measuring Ligand Efficacy at the Mu- Opioid Receptor Using A
    RESEARCH ARTICLE Measuring ligand efficacy at the mu- opioid receptor using a conformational biosensor Kathryn E Livingston1,2, Jacob P Mahoney1,2, Aashish Manglik3, Roger K Sunahara4, John R Traynor1,2* 1Department of Pharmacology, University of Michigan Medical School, Ann Arbor, United States; 2Edward F Domino Research Center, University of Michigan, Ann Arbor, United States; 3Department of Pharmaceutical Chemistry, School of Pharmacy, University of California San Francisco, San Francisco, United States; 4Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, United States Abstract The intrinsic efficacy of orthosteric ligands acting at G-protein-coupled receptors (GPCRs) reflects their ability to stabilize active receptor states (R*) and is a major determinant of their physiological effects. Here, we present a direct way to quantify the efficacy of ligands by measuring the binding of a R*-specific biosensor to purified receptor employing interferometry. As an example, we use the mu-opioid receptor (m-OR), a prototypic class A GPCR, and its active state sensor, nanobody-39 (Nb39). We demonstrate that ligands vary in their ability to recruit Nb39 to m- OR and describe methadone, loperamide, and PZM21 as ligands that support unique R* conformation(s) of m-OR. We further show that positive allosteric modulators of m-OR promote formation of R* in addition to enhancing promotion by orthosteric agonists. Finally, we demonstrate that the technique can be utilized with heterotrimeric G protein. The method is cell- free, signal transduction-independent and is generally applicable to GPCRs. DOI: https://doi.org/10.7554/eLife.32499.001 *For correspondence: jtraynor@umich.edu Competing interests: The authors declare that no Introduction competing interests exist.
    [Show full text]
  • Federal Register/Vol. 76, No. 36/Wednesday
    10068 Federal Register / Vol. 76, No. 36 / Wednesday, February 23, 2011 / Notices Drug Schedule registration to import a basic class of Dated: February 15, 2011. any controlled substance in schedule I Joseph T. Rannazzisi, Diethyltryptamine (7434) .............. I or II are, and will continue to be, Deputy Assistant Administrator, Office of Dimethyltryptamine (7435) ........... I required to demonstrate to the Deputy Diversion Control, Drug Enforcement Psilocybin (7437) .......................... I Assistant Administrator, Office of Administration. Psilocyn (7438) ............................. I [FR Doc. 2011–3948 Filed 2–22–11; 8:45 am] 1-[1-(2- I Diversion Control, Drug Enforcement Thienyl)cyclohexyl]piperidine Administration, that the requirements BILLING CODE 4410–09–P (7470). for such registration pursuant to 21 N-Benzylpiperazine (BZP) (7493) I U.S.C. 958(a); 21 U.S.C. 823(a); and 21 Heroin (9200) ............................... I CFR 1301.34(b), (c), (d), (e), and (f) are DEPARTMENT OF JUSTICE Normorphine (9313) ..................... I satisfied. Etonitazene (9624) ....................... I Drug Enforcement Administration Amphetamine (1100) .................... II Dated: February 15, 2011. Methamphetamine (1105) ............ II Joseph T. Rannazzisi, Manufacturer of Controlled Methylphenidate (1724) ................ II Substances; Notice of Application Deputy Assistant Administrator, Office of Amobarbital (2125) ....................... II Diversion Control, Drug Enforcement Pentobarbital (2270) ..................... II Administration.
    [Show full text]
  • Salvinorin A, TRK-820 and 3FLB) on ␬ Opioid Receptors in Vitro and Their Antipruritic and Antinociceptive Activities in Vivo
    0022-3565/05/3121-220–230$20.00 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Vol. 312, No. 1 Copyright © 2005 by The American Society for Pharmacology and Experimental Therapeutics 73668/1186283 JPET 312:220–230, 2005 Printed in U.S.A. Comparison of Pharmacological Activities of Three Distinct ␬ Ligands (Salvinorin A, TRK-820 and 3FLB) on ␬ Opioid Receptors in Vitro and Their Antipruritic and Antinociceptive Activities in Vivo Yulin Wang, Kang Tang, Saadet Inan, Daniel Siebert, Ulrike Holzgrabe, David Y.W. Lee, Peng Huang, Jian-Guo Li, Alan Cowan, and Lee-Yuan Liu-Chen Department of Pharmacology and Center for Substance Abuse Research, Temple University School of Medicine, Philadelphia, Pennsylvania (Y.W., K.T., S.I., P.H., J.-G.L., A.C., L.-Y.L.-C.); The Salvia divinorum Research and Information Center, Malibu, California (D.S.); Institut fur Pharmazie und Lebensmittelchemie, Universitat Wurzburg, Germany (U.H.); and McLean Hospital, Harvard Medical School, Belmont, Massachusetts (D.Y.W.L.) Received July 3, 2004; accepted September 21, 2004 ABSTRACT Salvinorin A, TRK-820 (17-cyclopropylmethyl-3,14␤-dihydroxy-4,5␣- agonist on MOR and DOR, whereas salvinorin A and 3FLB epoxy-6␤-[N-methyl-trans-3-(3-furyl) acrylamido]morphinan hydro- showed no activities on these receptors. Salvinorin A, TRK-820, chloride), and 3FLB (diethyl 2,4-di-[3-fluorophenyl]-3,7-dimethyl-3,7- and 3FLB caused internalization of the human KOR in a dose- diazabicyclo[3.3.1]nonane-9-one-1,5-dicarboxylate) are structurally dependent manner. Interestingly, although salvinorin A and distinctly different from U50,488H [(trans)-3,4-dichloro-N-methyl-N- U50,488H had similar potencies in stimulating [35S]GTP␥S bind- [2-(1-pyrrolidinyl)-cyclohexyl]benzeneacetamide methanesulfonate], ing, salvinorin A was about 40-fold less potent than U50,488H in the prototypic selective ␬ agonist.
    [Show full text]
  • Pentazocine Elisa Kit Instructions Product #103119 & 103116
    Neogen Corporation 944 Nandino Blvd., Lexington KY 40511 USA 800/477-8201 USA/Canada | 859/254-1221 Fax: 859/255-5532 | E-mail: inform@neogen.com | Web: www.neogen.com/Toxicology PENTAZOCINE ELISA KIT INSTRUCTIONS PRODUCT #103119 & 103116 INTENDED USE: For the determination of trace quantities of Pentazocine and/or other metabolites in human urine, blood, oral fluid. DESCRIPTION Neogen Corporation’s Pentazocine ELISA (Enzyme-Linked ImmunoSorbent Assay) test kit is a qualitative one-step kit designed for use as a screening device for the detection of drugs and/or their metabolites. The kit was designed for screening purposes and is intended for forensic use only. It is recommended that all suspect samples be confirmed by a quantitative method such as gas chromatography/mass spectrometry (GC/MS). ASSAY PRINCIPLES Neogen Corporation’s test kit operates on the basis of competition between the drug or its metabolite in the sample and the drug-enzyme conjugate for a limited number of antibody binding sites. First, the sample or control is added to the microplate. Next, the diluted drug-enzyme conjugate is added and the mixture is incubated at room temperature. During this incubation, the drug in the sample or the drug-enzyme conjugate binds to antibody immobilized in the microplate wells. After incubation, the plate is washed 3 times to remove any unbound sample or drug-enzyme conjugate. The presence of bound drug-enzyme conjugate is recognized by the addition of K-Blue® Substrate (TMB). After a 30 minute substrate incubation, the reaction is halted with the addition of Red Stop Solution.
    [Show full text]
  • Drug and Medication Classification Schedule
    KENTUCKY HORSE RACING COMMISSION UNIFORM DRUG, MEDICATION, AND SUBSTANCE CLASSIFICATION SCHEDULE KHRC 8-020-1 (11/2018) Class A drugs, medications, and substances are those (1) that have the highest potential to influence performance in the equine athlete, regardless of their approval by the United States Food and Drug Administration, or (2) that lack approval by the United States Food and Drug Administration but have pharmacologic effects similar to certain Class B drugs, medications, or substances that are approved by the United States Food and Drug Administration. Acecarbromal Bolasterone Cimaterol Divalproex Fluanisone Acetophenazine Boldione Citalopram Dixyrazine Fludiazepam Adinazolam Brimondine Cllibucaine Donepezil Flunitrazepam Alcuronium Bromazepam Clobazam Dopamine Fluopromazine Alfentanil Bromfenac Clocapramine Doxacurium Fluoresone Almotriptan Bromisovalum Clomethiazole Doxapram Fluoxetine Alphaprodine Bromocriptine Clomipramine Doxazosin Flupenthixol Alpidem Bromperidol Clonazepam Doxefazepam Flupirtine Alprazolam Brotizolam Clorazepate Doxepin Flurazepam Alprenolol Bufexamac Clormecaine Droperidol Fluspirilene Althesin Bupivacaine Clostebol Duloxetine Flutoprazepam Aminorex Buprenorphine Clothiapine Eletriptan Fluvoxamine Amisulpride Buspirone Clotiazepam Enalapril Formebolone Amitriptyline Bupropion Cloxazolam Enciprazine Fosinopril Amobarbital Butabartital Clozapine Endorphins Furzabol Amoxapine Butacaine Cobratoxin Enkephalins Galantamine Amperozide Butalbital Cocaine Ephedrine Gallamine Amphetamine Butanilicaine Codeine
    [Show full text]
  • Evaluation of Biased and Balanced Salvinorin a Analogs in Preclinical Models of Pain
    fnins-14-00765 July 18, 2020 Time: 20:26 # 1 ORIGINAL RESEARCH published: 21 July 2020 doi: 10.3389/fnins.2020.00765 Evaluation of Biased and Balanced Salvinorin A Analogs in Preclinical Models of Pain Kelly F. Paton1, Andrew Biggerstaff1, Sophia Kaska2, Rachel S. Crowley3, Anne C. La Flamme1,4, Thomas E. Prisinzano2,3 and Bronwyn M. Kivell1* 1 School of Biological Sciences, Centre for Biodiscovery, Faculty of Science, Victoria University of Wellington, Wellington, New Zealand, 2 Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY, United States, 3 Department of Medicinal Chemistry, School of Pharmacy, The University of Kansas, Lawrence, KS, United States, 4 Malaghan Institute of Medical Research, Wellington, New Zealand In the search for safer, non-addictive analgesics, kappa opioid receptor (KOPr) agonists are a potential target, as unlike mu-opioid analgesics, they do not have abuse potential. Salvinorin A (SalA) is a potent and selective KOPr agonist, however, clinical utility is limited by the short duration of action and aversive side effects. Biasing KOPr signaling toward G-protein activation has been highlighted as a key cellular mechanism to reduce the side effects of KOPr agonists. The present study investigated KOPr signaling bias and the acute antinociceptive effects and side effects of two novel analogs of SalA, Edited by: 16-Bromo SalA and 16-Ethynyl SalA. 16-Bromo SalA showed G-protein signaling bias, Dominique Massotte, whereas 16-Ethynyl SalA displayed balanced signaling properties. In the dose-response Université de Strasbourg, France tail-withdrawal assay, SalA, 16-Ethynyl SalA and 16-Bromo SalA were more potent than Reviewed by: Mariana Spetea, the traditional KOPr agonist U50,488, and 16-Ethynyl SalA was more efficacious.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2005/0112067 A1 Kumar Et Al
    US 2005O112067A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0112067 A1 Kumar et al. (43) Pub. Date: May 26, 2005 (54) METHODS AND COMPOSITIONS FOR (22) Filed: Nov. 26, 2003 DETERRING ABUSE OF OPOD CONTAINING DOSAGE FORMS Publication Classification (76) Inventors: Vijai Kumar, Morris Plains, NJ (US); (51) Int. Cl.' ........................ A61 K 49/00; A61K 31/485 David Dixon, Woodside, NY (US); (52) U.S. Cl. ........................................... 424/10.1; 514/282 Divya Tewari, Suffern, NY (US); Dilip B. Wadgaonkar, Suffern, NY (US) (57) ABSTRACT Correspondence Address: MORGAN, LEWIS & BOCKIUS LLP 1701 MARKET STREET This invention relates to an abuse deterrent dosage form of PHILADELPHIA, PA 19103-2921 (US) opioid analgesics, wherein an analgesically effective amount of opioid analgesic is combined with a polymer to form a (21) Appl. No.: 10/723,654 matrix. Patent Application Publication May 26, 2005 Sheet 1 of 9 US 2005/0112067 A1 Extractin f Opioids from immediatel controlled release formulations O O 103 99 E st 9 s ?o t e . o S3 vid x C b O SS Oxycodone Hydrocodone Oxyconting)" Hydrochloride Bitaritrate (Controlled release) (Immediate release) (immediate release) Fig. 1 Patent Application Publication May 26, 2005 Sheet 2 of 9 US 2005/0112067 A1 Extraction f opioids from anti-abuse formulation 100 8 O 6 O 4O 2 O O Oxycodone Hydrocodone Morphine Hydrochloride Bitatrate Sulfate (immediate release) (Immediate release) (Immediate release) Fig. 2 * Extraction process of opioids for anti-abuse properties is the same for figure l and figure 2. ** Marketed Oxycodone formulation from Purdue Pharma. Patent Application Publication May 26, 2005 Sheet 3 of 9 US 2005/0112067 A1 4.
    [Show full text]
  • Orll, a Novel Member of the Opioid Receptor Family Cloning, Functional
    FEBS Letters 341 (1994) 33-38 LETTERS ELSEVIER FEBS 13740 ORLl, a novel member of the opioid receptor family Cloning, functional expression and localization Catherine Mollereaua, Marc Parmentierb, Pierre Mailleux”, Jean-Luc Butoura, Christiane Moisanda, Pascale Chalond, Daniel Caputd, Gilbert Vassartb, Jean-Claude Meuniera,* ‘Institut de Pharmacologic et de Biologie structurale, Centre National de la Recherche Scientifque UPR 8221, 205 route de Narbonne, 31077 Toulouse Cedex, France bIRIBHN and ‘Unit4 de Recherche sur le Cerveau, ULB Campus Erasme, 808 route de Lennik, 1070 Bruxelles, Belgique dSanofi Elf Bio-Recherches, 31676 Lab?ge, France Received 31 January 1994 Abstract Selective PCR amplification of human and mouse genomic DNAs with oligonucleotides encoding highly conserved regions of the S-opioid and somatostatin receptors generated a human DNA probe (hOPO1, 761 bp) and its murine counterpart (mOP86, 447 bp). hOPO1 was used to screen a cDNA library from human brainstem. A clone (named hORL1) was isolated, sequenced and found to encode a protein of 370 amino acids whose primary structure displays the seven putative membrane-spanning domains of a G protein-coupled membrane receptor. The hORL1 receptor is most closely related to opioid receptors not only on structural (sequence) but also on functional grounds: hORL1 is 49-50% identical to the murine ,u-, 6- and rc-opioid receptors and, in CHO-Kl cells stably transfected with a pRc/CMV:hORLl construct, ORLl mediates inhibition of adenylyl cyclase by etorphine, a ‘universal’ (nonselective) opiate agonist. Yet, hORL1 appears not to be a typical opioid receptor. Neither is it a somatostatin or o (N-allylnormetazocine) receptor.
    [Show full text]
  • Salvia Divinorum and Salvinorin A: an Update on Pharmacology And
    Oliver Grundmann Stephen M. Phipps Salvia divinorum and Salvinorin A: An Update on Immo Zadezensky Veronika Butterweck Pharmacology and Analytical Methodology Review Abstract derstand and elucidate the various medicinal properties of the plant itself and to provide the legislative authorities with enough Salvia divinorum (Lamiaceae) has been used for centuries by the information to cast judgement on S. divinorum. Mazatecan culture and has gained popularity as a recreational drug in recent years. Its potent hallucinogenic effects seen in Key words case reports has triggered research and led to the discovery of Salvia divinorum ´ Lamiaceae ´ depression ´ opioid antagonist ´ the first highly selective non-nitrogenous k opioid receptor ago- pharmacokinetics ´ pharmacology ´ toxicology ´ salvinorin A nist salvinorin A. This review critically evaluates the reported pharmacological and toxicological properties of S. divinorum Abbreviations and one of its major compounds salvinorin A, its pharmacokinet- CNS: central nervous system ic profile, and the analytical methods developed so far for its de- FST: forced swimming test tection and quantification. Recent research puts a strong empha- i.t.: intrathecal sis on salvinorin A, which has been shown to be a selective opioid KOR: kappa opioid receptor antagonist and is believed to have further beneficial properties, LSD: lysergic acid diethylamide rather than the leaf extract of S. divinorum. Currently animal norBNI: norbinaltorphimine studies show a rapid onset of action and short distribution and p.o.: per os 1039 elimination half-lives as well as a lack of evidence of short- or s.c.: subcutaneous long-term toxicity. Salvinorin A seems to be the most promising ssp.: subspecies approach to new treatment options for a variety of CNS illnesses.
    [Show full text]